Motley Rice reached an anti-trust settlement to resolve litigation alleging drug manufacturers Boehringer Ingelheim and Teva Pharmaceutical engaged in an alleged pay-for-delay scheme to block generic competition for stroke medication Aggrenox®.
Motley Rice reached a $43 million settlement with Medtronic, Inc. on behalf of shareholders who purchased the company’s common stock and suffered losses.
The Connecticut Law Tribune has recognized Motley Rice consumer fraud attorney Mathew Jasinski as a “New Leader in Law” for 2018.
The National Law Journal announced finalists for its 2018 Elite Trial Lawyers and has named Motley Rice a finalist in four categories for its “exemplary performance in cutting edge work.”